Immunitor Awarded the Key U.S. Patent Related to Oral Vaccine Technology Platform
29 Novembre 2010 - 1:38PM
Immune Network Ltd. (Pink Sheets:IMMFF), advises that its potential
acquisition, Immunitor USA Inc., has been issued a key patent by
the U.S. Patent and Trademark Office (USPTO). The patent (US
7,838,006 "Viral vaccine composition, process and methods of use")
contains claims covering the composition of matter for Immunitor's
lead product, V5. The patent also covers the process of making and
use of the matter for treating and preventing the broad range of
infectious diseases. Immunitor was previously awarded a U.S.
patent covering another lead compound specifically designed for
treatment of AIDS (US 7,384,637). According to Vichai Jirathitikal,
the principal inventor on these two patents, "The USPTO has
validated the novelty and utility of Immunitor's technology and its
use in the treatment and prophylaxis of a range of most diverse
diseases and conditions." The co-inventor, Aldar Bourinbaiar,
Immunitor's CEO, added: "With the issuance of these two patents,
our lead programs are further protected, significantly enhancing
their commercial value."
Over the course of the company's development, Immunitor has
achieved a broad and deep intellectual-property position in the
orally delivered immunotherapeutics area. The company's patent
portfolio now includes more than eight pending patents (including
two international), with at least two dozen scientific publications
in the peer-reviewed medical literature describing various aspects
of the technology in infectious and autoimmune diseases, cancer,
and metabolic diseases such as atherosclerosis and obesity. The
combined annual market for these and related indications is close
to $100 billion. Immunitor is the industry leader in tableted oral
vaccines and immunotherapies. During the past three years Immunitor
completed two phase II clinical trials using V5 for treatment of
chronic hepatitis B and hepatitis C. This year Immunitor seized
upon an unexpected clinical outcome, which revealed the intriguing
potential of V5 in curing tuberculosis in almost 95% of patients
within one month. The results of the first trial in patients with
tuberculosis who were co-infected with hepatitis C virus and HIV
were published in October issue of Journal of Vaccines and
Vaccination
(http://www.omicsonline.org/2157-7560/2157-7560-1-103.php). Patient
enrollment for two additional phase 2b placebo-controlled trials
involving 120 patients with difficult-to-treat forms of
tuberculosis has been just completed in Ukraine and results are
anticipated in early 2011.
To date, all clinical trials of V5 have provided strong evidence
of an excellent safety profile and provided insights into the
unparalleled efficacy that will guide Immunitor in the design of
follow-on hepatitis and tuberculosis studies, which are now being
arranged in South Africa, Pakistan, India and China. Immune Network
is continuing its work toward meeting the pre-conditions for
completion of a merger or similar transaction with
Immunitor. Several aspects of the updated corporation and its
anticipated transactions will be announced early in December
2010.
A temporary website for Immune Network is at
http://www.immune-network.com. The Immune Network Ltd. logo is
available at http://www.globenewswire.com/newsroom/prs/?pkgid=8008
.
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
IMMFF@yahoo.com
Grafico Azioni Omni Bridgeway (PK) (USOTC:IMMFF)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Omni Bridgeway (PK) (USOTC:IMMFF)
Storico
Da Lug 2023 a Lug 2024